New Delhi, Feb. 2 -- The Union Budget 2026 has signalled a sustained policy push for India's pharmaceutical and life sciences sector, with a strong emphasis on biopharma innovation, research infrastructure and affordability, even as direct tax incentives remain unchanged, noted EY's Budget sectoral alert.

According to EY's Budget 2026 pharma alert, this year's Budget offers a steady direction for the pharma and life sciences sector, with a clear emphasis on building biopharma capabilities, underlining the government's intent to strengthen India's position as a global biopharma hub

A key highlight is the announcement of the Rs 10,000 crore Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation)...